Test Price
2,800 AED✅ Home Collection Available
CALR Exon 9 Mutation Analysis (NGS) in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing, validated for variant detection at 2% VAF.
- Premium Logistics: VIP Mobile Phlebotomy & temperature-controlled cold-chain home collection, available daily from 8 AM to 11 PM, ensuring DNA integrity.
- Clinical Guidance: Post-test telephonic interpretation by DHA-licensed specialists, integrated with full blood count correlation.
- Insurance Verification: Direct billing confirmation via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CALR exon 9 mutation analysis employs next-generation sequencing (NGS) to detect somatic insertions and deletions in the calreticulin gene. This test is essential for diagnosing Philadelphia‑negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia and primary myelofibrosis, and provides critical prognostic stratification distinct from JAK2‑ and MPL‑mutated cases. NGS enables comprehensive coverage of all exon 9 indels, including rare 3‑bp and 5‑bp variants, at a sensitivity of ≥99.9% at 2% variant allele frequency (VAF).
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS), covering all exon 9 indels | Sanger sequencing, limited to known hotspots |
| Analytical Sensitivity | ≥99.9% variant detection at 2% VAF | ~95% at 15‑20% VAF |
| Turnaround Time | 10–15 business days | 7–10 business days |
| Mutation Coverage | Full exon 9, including rare 5‑bp and 3‑bp insertions/deletions | Common 52‑bp deletion and 5‑bp insertion only |
Physician Insight & Safety Protocols
“CALR exon 9 mutations are definitive driver variants in MPNs and offer important prognostic information. However, this genetic result must be interpreted alongside complete blood counts, bone marrow histology, and clinical presentation. A positive finding does not replace comprehensive hematologic evaluation. Always discuss results with your treating physician before making any treatment changes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory: Genetic Testing & Medication Management
Do not stop or adjust any prescribed medication without consulting your doctor. This test informs long‑term prognosis and treatment planning, not acute therapeutic changes. Continue all current therapies as directed until your hematologist reviews the report.
Safety & Exclusion Criteria
- Exclusion: Active chemotherapy or radiotherapy within 2 weeks; known severe hemophilia or uncontrolled bleeding disorder (contraindication for blood draw).
- Emergency Red Flags: If you experience spontaneous severe bleeding, sudden numbness or confusion (stroke symptoms), deep vein thrombosis (leg swelling/pain), or leukostasis (visual changes, respiratory distress), seek immediate emergency care – this genetic test is not intended for acute diagnosis.
Patient FAQ & Clinical Guidance
1. What is the clinical significance of CALR exon 9 mutations?
CALR exon 9 mutations are driver alterations in about 25% of essential thrombocythemia and 35% of primary myelofibrosis cases, according to WHO classification. They define a distinct MPN subtype with a more favorable prognosis compared to JAK2‑mutated disease. These mutations are mutually exclusive with JAK2 and MPL, making their detection essential for accurate diagnosis and risk stratification.
2. How should I prepare for the CALR exon 9 blood collection at home?
No fasting is required. Stay well‑hydrated before the phlebotomist arrives. Please provide your clinical history, current medication list, and any previous genetic reports to the mobile care team. A sterile, cold‑chain transport kit will be used to preserve DNA from collection to our laboratory in Dubai Healthcare City.
3. Are CALR exon 9 results covered by UAE health insurance?
Many UAE insurers require preauthorization for advanced genetic testing. Our team can verify your coverage directly via WhatsApp at +971 54 548 8731 before scheduling, and we provide the appropriate ICD‑10 codes (D47.3, D47.4) for claim submission.
UAE Regulatory & Data Privacy Adherence
This test is performed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and used solely for diagnostic purposes. Patient consent and confidentiality are guaranteed under Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | CALR Exon 9 Mutation Analysis (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 10–15 Business Days |
| Sample Type / Matrix | Whole Blood (Peripheral) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD‑10‑CM Code | D47.3 (Essential Thrombocythemia), D47.4 (Primary Myelofibrosis) |
| LOINC Code | 94477‑5 (CALR gene mutation analysis in Blood by Sequencing) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians